Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access ...

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone in patients with high-risk non–muscle invasive bladder cancer (NMIBC) found ...

Clinical Brief: Treatment Options for Recurrent Metastatic Prostate Cancer. Main Discussion Topics. Triplet Therapy: Androgen deprivation therapy (ADT) with docetaxel chemotherapy and an androgen ...

The ODAC meeting was called to discuss the submitted new drug application (NDA) for UGN-102, which the agency previously accepted in October 2024, issuing a Prescription Drug User Fee Act (PDUFA) ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted in a unanimous 0-8 decision that the TALAPRO-2 data on talazoparib (Talzenna) in combination with enzalutamide (Xtandi) is not sufficient to ...

CT scans remain the most common initial imaging modality for renal mass detection. MRI offers additional sequencing capabilities for better tumor characterization. Ultrasound primarily helps determine ...

Landmark randomized trials conducted in the early 2000s demonstrated a survival advantage for up-front cytoreductive surgery in combination with interferon alfa compared with interferon alpha alone, ...

Treatment Approaches and Role of Biopsy. Main Discussion Topics: Masses under 2 cm are typically managed with active surveillance. Options for masses that are 2 to 4 cm include ablation (eg, ...

Risk Stratification Systems: The panel discussed various risk classification systems for non–muscle-invasive bladder cancer (NMIBC), comparing AUA, EU, and international bladder cancer group ...

A panelist discusses how the outcomes of this study broadly align with real-world treatment patterns and clinical experiences, where enzalutamide and darolutamide both demonstrate efficacy in ...

Specific tumor features—such as papillary architecture and the presence of carcinoma in situ (CIS)—play a critical role in shaping treatment decisions for NMIBC. Papillary tumors, particularly ...